Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
about
Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor RadiosensitizationHsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteinsThe HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damageRadiosensitization of normoxic and hypoxic h1339 lung tumor cells by heat shock protein 90 inhibition is independent of hypoxia inducible factor-1αHeat shock protein 90 inhibitor NVP-AUY922 exerts potent activity against adult T-cell leukemia-lymphoma cells.The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: A predictive marker and promising target for radiosensitizationThe novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.Increased radiosensitivity and radiothermosensitivity of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines treated with the novel Hsp90 inhibitor NVP-HSP990.Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment.PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.A novel HSP90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor control in models of colorectal cancer.Current concepts in clinical radiation oncology.HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies.Enhancing radiation therapy for patients with glioblastoma.Gamma histone 2AX (γ-H2AX)as a predictive tool in radiation oncology.Apoptosis and molecular targeting therapy in cancer.Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities.Advances in HSP27 and HSP90-targeting strategies for glioblastoma.TAS-116, a Novel Hsp90 Inhibitor, Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation.Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status.Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90α.Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia.The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.Regulation of Ubiquitin-like with Plant Homeodomain and RING Finger Domain 1 (UHRF1) Protein Stability by Heat Shock Protein 90 Chaperone Machinery.Irradiation facilitates the inhibitory effect of the heat shock protein 90 inhibitor NVP-BEP800 on the proliferation of malignant glioblastoma cells through attenuation of the upregulation of heat shock protein 70.Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: The role of drug-irradiation schedule.Hsp90 Inhibitors NVP-AUY922 and NVP-BEP800 May Exert a Significant Radiosensitization on Tumor Cells along with a Cell Type-Specific Cytotoxicity.Heat shock protein 90 (hsp90) expression and breast cancer.Heat shock proteins and DNA repair mechanisms: an updated overview.The S100A6 calcium-binding protein regulates endothelial cell-cycle progression and senescence.Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor explants.Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.
P2860
Q26771165-9CD39630-4CA4-4ED4-B21F-2B4CA0A89539Q28485399-877193D1-D751-4A74-8366-22B4272DD158Q28730558-5435159F-10A2-42FD-B416-3AFD19A0A4E0Q34162720-0C1A8E00-4504-4CF4-9172-FB5A6A56A86BQ35051987-B4C36705-78F5-46D8-90F1-77E314AF0227Q35236805-0546C4B7-F3D7-4752-9D2F-C0046EBEAE05Q36307472-BB863186-C4F4-41FE-9CFB-8EFADB8B3128Q36546425-A9132D5A-6F3C-4DB7-906F-C9DADC647B81Q36691054-E691888E-B8B2-4F07-B94A-D65563247FFBQ37031569-AFB865D1-E042-43E7-84B7-12BD627831E6Q37301093-2E8C47E2-D3FF-4579-8809-6679C8D690E8Q37470072-0A30418B-A978-4A4F-AE98-3CC03C1146C6Q37536525-EBB0FE4A-511B-40DF-A395-522636533143Q37603804-63479B11-4C1A-473D-9D6C-5437CFD4E66AQ37615630-58D133D8-B9C3-4FDE-8902-3EE6EB0B6FE5Q38029728-D1FB5B07-D58C-4299-B0C1-0213C86F115CQ38101608-62874C96-E26D-4AF5-889D-78C2F8A2F9F4Q38194616-1CA66166-C12E-4E97-AAC8-DEC4A2412451Q38228349-A717A7AC-4CBA-4191-B4C4-2B956E02A59AQ38706839-5490132D-55E4-454A-86F5-037EBC49E65CQ38722149-85A5F066-F6B4-475D-A1BF-9F4B93F11DF3Q38722571-83E6BFA3-CE90-4CD6-B5A4-5F594707B8B2Q39027066-F519692E-0D76-47CB-A1BC-7E4BBCAA0B14Q39203018-68A0D661-120D-4AB0-AAF8-5DE8EC177AA7Q39331935-84BAA6FE-F8DE-4F71-9A65-CED8779EA5BEQ39375187-4B3ADD83-DB71-4356-B8EF-E04D28BBDF63Q39404697-D57EB20F-944F-42A9-8A87-0EBE7511D518Q39431815-D0011C57-149A-4361-B844-5879BD62ACD0Q39567800-B30081A4-0523-4B26-A35F-F010E158DB4FQ41106970-D97CA43A-E8E7-4847-B1EE-671BB6D2814DQ41827236-C15B4952-4714-4A1E-AF19-6B6A71D25C34Q42363700-CF96F0EA-0DF9-4C9B-A750-E1A7D18AF481Q42427997-4770259F-9C26-4B64-A926-C085AC76FBE9Q42922811-5BCBF99F-2F1F-4D06-9D2B-F70BBD2BF46FQ47738263-3EAAE7D7-B328-49C3-9923-F8E93FB5E3AAQ50551664-B2ECC094-D5DC-498D-B631-7D3FB6FD6E3EQ52327617-6C794E02-F89B-49A4-9418-F1D7FC8EB42AQ52676453-13F44877-FC98-4E81-8CA2-1B8371772D6B
P2860
Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Novel HSP90 inhibitors, NVP-AU ...... damage and repair protraction.
@en
Novel HSP90 inhibitors, NVP-AU ...... damage and repair protraction.
@nl
type
label
Novel HSP90 inhibitors, NVP-AU ...... damage and repair protraction.
@en
Novel HSP90 inhibitors, NVP-AU ...... damage and repair protraction.
@nl
prefLabel
Novel HSP90 inhibitors, NVP-AU ...... damage and repair protraction.
@en
Novel HSP90 inhibitors, NVP-AU ...... damage and repair protraction.
@nl
P2093
P2860
P356
P1476
Novel HSP90 inhibitors, NVP-AU ...... damage and repair protraction.
@en
P2093
C S Djuzenova
M Chatterjee
M R Jensen
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605683
P407
P577
2010-05-01T00:00:00Z